

Xbrane Biopharma AB ("Xbrane" or the "Company") announces changes to the number of shares and votes in the Company.

The number of shares and votes in Xbrane have changed following the issue of 105,000 shares during June through exercise of warrants under LTIP 2019, adopted at the annual general meeting 2019.

As of June 30, 2022, the total number of shares and votes in the Company amounts to 25,144,906. The Company's registered share capital amounts to SEK 5,637,137.439365.

Contacts

Martin Åmark, CEO
M: +46 76 309 37 77
E: martin.amark@xbrane.com

Anette Lindqvist, CFO/IR
M: +46 76 325 60 90
E: anette.lindqvist@xbrane.com

About Us

Xbrane Biopharma AB develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane has a portfolio of biosimilar candidates targeting SEK 332 billion in annual sales of the respective reference products, with the leading one under registration in Europe. Xbrane's head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit www.xbrane.com

This information is information that Xbrane Biopharma is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2022-06-30 12:00 CEST.

Attachments

[Xbrane Biopharma AB \("Xbrane" or the "Company"\) announces changes to the number of shares and votes in the Company.](#)